Psychedelic Research Group

Psychedelic Research Group

Menu

  • Home
  • Our Research
  • News Articles
  • Blog
  • Article Grid
  • Videos

Science policy

Psychoactive substances ban will ‘end brain research’ in Britain, experts warn

Psychoactive substances ban will ‘end brain research’ in Britain, experts warn

David Nutt, former government chief drugs adviser, says banning of legal highs has already been destructive to Parkinson’s and anti-smoking research

The Administrator August 26, 2015October 15, 2015 News Articles Read more

Focus

The Psychedelic Research Group at Imperial focuses on two main research areas:
  1.  The action of psychedelic drugs in the brain.
  2. Their clinical utility, e.g. as aides to psychotherapy, with a particular focus on depression.
The group is lead by Dr Robin Carhart-Harris.

Search

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Blog
News Articles
Published Articles

Twitter

Psychedelic Research Group
4 days ago
Robin Carhart-Harris's Twitter avatar
Robin Carhart-Harris
@RCarhartHarris

Effects of psilocybin therapy on personality structure. - PubMed - NCBI t.co/TTEuHN72Uj

Retweeted by Imperial PRG
  • Reply
  • Retweet 26
  • Like 56
6 days ago
Imperial PRG's Twitter avatar
Imperial PRG
@Imperial_PRG

Please share far and wide: t.co/uPKgQcPXKf

  • Reply
  • Retweet 2
  • Like 4
June 17, 2018
Psychedelic Survey's Twitter avatar
Psychedelic Survey
@psychesurvey

Check out this little short video taking you through what the Global Psychedelic Survey study intends to look at! 🔍… t.co/9aF2XfIpG0

Retweeted by Imperial PRG
  • Reply
  • Retweet 5
  • Like 10
June 17, 2018
Robin Carhart-Harris's Twitter avatar
Robin Carhart-Harris
@RCarhartHarris

Watch “All you need to know about the Global Psychedelic Survey in 3min” on #Vimeo t.co/WB4Hgi1drz

Retweeted by Imperial PRG
  • Reply
  • Retweet 6
  • Like 9
June 11, 2018
Imperial PRG's Twitter avatar
Imperial PRG
@Imperial_PRG

@4a5f7087e44e421 @RCarhartHarris Yes

  • Reply
  • Retweet 0
  • Like 2

F1000 Prime Recommendation

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression

Roseman, L., Nutt D.J., Carhart-Harris R.


Access the recommendation on F1000Prime.

Our Papers

  • Mourning and melancholia revisitedMourning and melancholia revisited
  • Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early PsychosisFunctional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis
  • The default mode ego functions and free energyThe default mode ego functions and free energy
  • Neural correlates of the LSD experience revealed by multimodal neuroimagingNeural correlates of the LSD experience revealed by multimodal neuroimaging
  • Homological scaffolds of brain functional networksHomological scaffolds of brain functional networks

News Articles about us

  • LSD’s impact on the brain revealed in groundbreaking imagesLSD’s impact on the brain revealed in groundbreaking images
  • Healing trip: how psychedelic drugs could help treat depressionHealing trip: how psychedelic drugs could help treat depression
  • 2016’s best bits: breakthroughs in science2016’s best bits: breakthroughs in science
  • Depressed? Your doctor might soon prescribe ketamine
  • David Nutt – The Psychedelic CrusaderDavid Nutt – The Psychedelic Crusader

Contact Us

Any questions, please feel free to contact us.

Archives

Copyright © 2018 Psychedelic Research Group. Powered by WordPress. Theme: Spacious by ThemeGrill.